Third Time's The Charm? Orexigen Terminates CONVENE
This article was originally published in Scrip
You may also be interested in...
The Japanese pharma says it will discuss the data with US FDA, with hopes of potential to incorporate secondary endpoint data in labeling.
Orexigen has a tough climb ahead as it sets out without a US partner to boost sales for its obesity drug Contrave with the goal of profitability by 2019, but it appears that doctors, patients and payers are becoming more open to pharmaceutical treatment.
The Medicines Company, Amarin and Geron have all reported interim analyses for clinical studies recently and investors have been left disappointed. Were we better off without the interim analysis?